Keyphrases
Melanoma Cells
100%
MEK Inhibitor (MEKi)
100%
MTOR Complex 2 (mTORC2)
100%
BRAF-mutant Melanoma
100%
Rictor
100%
BRAF Inhibitor (BRAFi)
50%
Metastatic Melanoma
35%
Tumor
14%
Targeted Therapy
14%
Nicotinamide Phosphoribosyltransferase (NAMPT)
14%
BRAF V600E
14%
Proteomic Screening
14%
Intratumor
14%
Mitochondrial Respiration
14%
Expression Analysis
7%
Drug Target
7%
Therapeutic Strategies
7%
Prognostic Value
7%
Overall Survival
7%
Tumor Subtype
7%
Nave
7%
Clinical Outcomes
7%
Pharmacological Inhibitors
7%
Gene Signature
7%
Potential Therapeutics
7%
Molecular Signature
7%
Xenograft
7%
Energy Production
7%
Mitochondrial Electron Transport Chain
7%
Patient Database
7%
Target Molecule
7%
Drug Exposure
7%
Electron Transport Chain
7%
Chemotherapy Resistance
7%
Signaling Complex
7%
Oncogenic Drivers
7%
Cancer Genome Atlas
7%
Gene Set Enrichment Analysis
7%
Therapeutic Vulnerabilities
7%
Early Adaptation
7%
Seahorse Analysis
7%
Survival Signature
7%
Adaptation Phase
7%
Cutaneous Metastatic Melanoma
7%
Tumor Suppress
7%
Medicine and Dentistry
Neoplasm
100%
Downregulation
100%
Melanoma Cell
100%
Metastatic Melanoma
100%
MEK Inhibitor
50%
Targeted Therapy
33%
Nicotinamide Phosphoribosyltransferase
33%
Respiratory Chain
33%
Mitochondrial Respiration
33%
Proteomics
33%
In Vitro
16%
Overall Survival
16%
Carcinogenesis
16%
Drug Delivery System
16%
Xenograft
16%
Drug Exposure
16%
Melanoma Cell Line
16%
The Cancer Genome Atlas
16%
Targeting Protein
16%
Genome-Wide Analysis of Gene Expression
16%
Biochemistry, Genetics and Molecular Biology
Downregulation
100%
RICTOR
100%
MEK Inhibitor
21%
Nicotinamide Phosphoribosyltransferase
14%
Electron Transport Chain
14%
Mitochondrial Respiration
14%
Proteomics
14%
Overall Survival
7%
Carcinogenesis
7%
Gene Signature
7%
Energy Yield
7%
Drug Targeting
7%
Targeting Protein
7%
Drug Exposure
7%
Seahorse
7%
Genome-Wide Analysis of Gene Expression
7%